Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Kalydeco was initially approved in 2012 to treat patients aged over six with a single mutation of the cystic fibrosis transmembrane regulator (CFTR) gene - known as G551D - which affects around ...

EMA clears Vertex' Symkevi + Kalydeco for cystic fibrosis in children aged 6-11, the first disease-modifying therapy patients in this age group with two F508del mutations or one F508del and a ...

and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause ...

The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...

After hours: 7:56:30 p.m. EST ...

AbbVie, Vertex Pharmaceuticals, Eli Lilly and Company, Thermo Fisher Scientific, and Colgate-Palmolive are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool.

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective raised by HC Wainwright from $535.00 to $550.00 in a research note released on Friday,Benzinga reports. HC Wainwright ...